Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds.
The neuraminidase (NA) inhibitors oseltamivir and zanamivir are the first-line of defense against potentially fatal variants of influenza A pandemic strains. However, if resistant virus strains start to arise easily or at a high frequency, a new anti-influenza strategy will be necessary. This study aimed to investigate if and to what extent NA inhibitor-resistant mutants exist in the wild population of influenza A viruses that inhabit wild birds. NA sequences of all NA subtypes available from 5490 avian, 379 swine and 122 environmental isolates were extracted from NCBI databases. In addition, a dataset containing 230 virus isolates from mallard collected at Ottenby Bird Observatory (Öland, Sweden) was analyzed. Isolated NA RNA fragments from Ottenby were transformed to cDNA by RT-PCR, which was followed by sequencing. The analysis of genotypic profiles for NAs from both data sets in regard to antiviral resistance mutations was performed using bioinformatics tools. All 6221 sequences were scanned for oseltamivir- (I117V, E119V, D198N, I222V, H274Y, R292K, N294S and I314V) and zanamivir-related mutations (V116A, R118K, E119G/A/D, Q136K, D151E, R152K, R224K, E276D, R292K and R371K). Of the sequences from the avian NCBI dataset, 132 (2.4%) carried at least one, or in two cases even two and three, NA inhibitor resistance mutations. Swine and environmental isolates from the same data set had 18 (4.75%) and one (0.82%) mutant, respectively, with at least one mutation. The Ottenby sequences carried at least one mutation in 15 cases (6.52%). Therefore, resistant strains were more frequently found in Ottenby samples than in NCBI data sets. However, it is still uncertain if these mutations are the result of natural variations in the viruses or if they are induced by the selective pressure of xenobiotics (e.g., oseltamivir, zanamivir).
Section for Zoonotic Ecology and Epidemiology, Linneaus University, Kalmar, Sweden. goran.orozovic@lnu.se
Goran
G
Orozovic
Kanita
K
Orozovic
Johan
J
Lennerstrand
Björn
B
Olsen
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D019295:Computational Biology / Q000379:methods; D030561:Databases, Nucleic Acid; D024882:Drug Resistance, Viral / Q000235:genetics*; D004372:Ducks; D009980:Influenza A virus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D005585:Influenza in Birds / Q000188:drug therapy / Q000821:virology*; D020125:Mutation, Missense; D053139:Oseltamivir / Q000494:pharmacology*; D012367:RNA, Viral / Q000302:isolation & purification; D017422:Sequence Analysis, DNA; D013552:Swine; D053243:Zanamivir / Q000494:pharmacology*
D000998:Antiviral Agents; D012367:RNA, Viral; D053139:Oseltamivir; D053243:Zanamivir
J Gen Virol. 2010 Apr;91(Pt 4):949-59
20016036
Euro Surveill. 2010 Apr 08;15(14):
20394718
PLoS Pathog. 2010 Jul 22;6(7):e1001005
20661479
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40
16585506
Antimicrob Agents Chemother. 2008 Oct;52(10):3484-91
18694948
Antimicrob Agents Chemother. 2001 Oct;45(10):2723-32
11557461
Virus Res. 2010 Jan;147(1):40-6
19835919
J Virol. 2009 Oct;83(20):10366-73
19641000
J Virol Methods. 2010 Dec;170(1-2):94-8
20837063
J Clin Virol. 2009 Jul;45(3):169-73
19540800
Chemosphere. 2009 Mar;75(1):28-33
19124147
Emerg Infect Dis. 2007 Mar;13(3):404-11
17552093
Antiviral Res. 2010 Feb;85(2):381-8
19917319
PLoS One. 2007 Oct 03;2(10):e986
17912363
Influenza Other Respir Viruses. 2007 Jan;1(1):19-25
19453476
Antiviral Res. 2000 Jul;47(1):1-17
10930642
Antiviral Res. 2007 Mar;73(3):228-31
17112602
J Clin Virol. 2008 Jan;41(1):13-9
18055254
Antiviral Res. 2008 Feb;77(2):163-6
17919743
Environ Health Perspect. 2007 Jan;115(1):102-6
17366827
Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8
11709315
PLoS One. 2009 Jun 26;4(6):e6064
19557131
PLoS Pathog. 2008 May 30;4(5):e1000076
18516303
PLoS One. 2007 Dec 12;2(12):e1305
18074029
Science. 2006 Apr 21;312(5772):384-8
16627734
Virology. 1999 Oct 25;263(2):323-38
10544106
Antiviral Res. 2007 Dec;76(3):263-6
17868928
PLoS Pathog. 2007 May 11;3(5):e61
17500589
Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93
18676886
Emerg Infect Dis. 2005 Oct;11(10):1545-51
16318694
Annu Rev Genet. 2002;36:305-32
12429695
Vet Microbiol. 2008 Sep 18;131(1-2):82-92
18403137
Rev Med Virol. 2003 Mar-Apr;13(2):85-97
12627392
Antiviral Res. 2005 Oct;68(1):43-8
16125799
J Virol. 2007 Nov;81(22):12418-26
17855542
Annu Rev Med. 2000;51:407-21
10774473
Antiviral Res. 2004 Apr;62(1):37-45
15026200
PLoS Pathog. 2010 May 27;6(5):e1000933
20523902
Science. 2010 Jun 4;328(5983):1272-5
20522774
J Virol. 2006 Sep;80(17):8787-95
16912325
Environ Health Perspect. 2010 Jan;118(1):103-7
20056566
Cell Host Microbe. 2010 Jun 25;7(6):440-51
20542248
Clin Infect Dis. 2009 May 1;48(9):1254-6
19323631
J Gen Virol. 2007 Jul;88(Pt 7):2035-2041
17554038
J Infect Chemother. 2006 Aug;12(4):167-71
16944252
Antimicrob Agents Chemother. 2009 Oct;53(10):4433-40
19651908
Infect Genet Evol. 2009 Mar;9(2):169-78
19022400
JAMA. 2009 Mar 11;301(10):1034-41
19255110
Adv Virus Res. 2008;72:127-54
19081490
J Virol. 1997 May;71(5):3385-90
9094607
Arch Virol. 2001 Dec;146(12):2275-89
11811679
Virus Res. 2004 Jul;103(1-2):199-203
15163510
Antiviral Res. 2002 May;54(2):79-88
12062393
Emerg Infect Dis. 2006 Jan;12(1):55-60
16494718
Viruses. 2010 Aug;2(8):1510-29
21994692
Nature. 2006 Jul 27;442(7101):448-52
16642006
Antivir Ther. 2007;12(4 Pt B):603-16
17944268
JAMA. 2009 Mar 11;301(10):1066-9
19255112
Antiviral Res. 2006 Jul;70(3):121-31
16516984
J Clin Virol. 2008 Jan;41(1):20-4
18065262